Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zongertinib tablets).
HERNEXEOS is currently under investigation for first-line use in treatment-naive patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
The CNPV program looks to reduce the review process from a typical tome-scale of 10-12 months to one to two months, while maintaining the FDA's rigorous safety and efficacy standards.
This honour is claimed to reflect the potential of HERNEXEOS to meet critical patient requirements for this rare and aggressive cancer.
The FDA chose HERNEXEOS for the CNPV program.
enGene reports 62% six-month complete response rate for detalimogene in LEGEND trial
Nurami Medical completes Phase 1 milestones in EIC-backed grant for Artifix
Avingtrans subsidiary Adaptix secures FDA clearance for 3D orthopaedic imaging system
Innate Pharma cleared by FDA to launch TELLOMAK 3 Phase 3 trial of lacutamab in CTCL
Exact Sciences secures US exclusive license to Freenome's blood-based colorectal cancer tests
MavriX Bio reports first patient dosed in Phase 1/2 trial of MVX-220 for AS
Johnson & Johnson's DARZALEX FASPRO receives US FDA approval
Calico Life Sciences' ABBV-CLS-628S granted US FDA Orphan Drug Designation
Galderma secures US FDA approval for Restylane Lyft to enhance chin profile
Spinogenix reveals positive SPG302 topline results from Phase 2a study for treatment of ALS